Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1987 4
1988 2
1989 6
1990 5
1991 8
1992 9
1993 5
1994 2
1995 2
1996 4
1997 8
1998 7
1999 4
2000 4
2001 5
2002 4
2003 3
2004 3
2005 3
2006 5
2007 2
2008 6
2009 4
2010 4
2011 6
2012 2
2013 5
2014 7
2015 4
2016 9
2017 13
2018 11
2019 7
2020 23
2021 5
2022 7
2023 7
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin in Patients with Chronic Kidney Disease.
The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. The EMPA-KIDNEY Collaborative Group, et al. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. N Engl J Med. 2023. PMID: 36331190 Free PMC article. Clinical Trial.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Zinman B, et al. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. N Engl J Med. 2015. PMID: 26378978 Free article. Clinical Trial.
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.
Fioretto P, Del Prato S, Buse JB, Goldenberg R, Giorgino F, Reyner D, Langkilde AM, Sjöström CD, Sartipy P; DERIVE Study Investigators. Fioretto P, et al. Diabetes Obes Metab. 2018 Nov;20(11):2532-2540. doi: 10.1111/dom.13413. Epub 2018 Jul 10. Diabetes Obes Metab. 2018. PMID: 29888547 Free PMC article. Clinical Trial.
Atherogenic dyslipidemia and diabetic nephropathy.
Russo G, Piscitelli P, Giandalia A, Viazzi F, Pontremoli R, Fioretto P, De Cosmo S. Russo G, et al. Among authors: fioretto p. J Nephrol. 2020 Oct;33(5):1001-1008. doi: 10.1007/s40620-020-00739-8. Epub 2020 Apr 23. J Nephrol. 2020. PMID: 32328901 Review.
The authors reply.
Kohan DE, Fioretto P, Tang W, List JF. Kohan DE, et al. Among authors: fioretto p. Kidney Int. 2014 Dec;86(6):1272. doi: 10.1038/ki.2014.291. Kidney Int. 2014. PMID: 25427094 Free article. No abstract available.
Combination therapy for kidney disease in people with diabetes mellitus.
van Raalte DH, Bjornstad P, Cherney DZI, de Boer IH, Fioretto P, Gordin D, Persson F, Rosas SE, Rossing P, Schaub JA, Tuttle K, Waikar SS, Heerspink HJL. van Raalte DH, et al. Among authors: fioretto p. Nat Rev Nephrol. 2024 Apr 3. doi: 10.1038/s41581-024-00827-z. Online ahead of print. Nat Rev Nephrol. 2024. PMID: 38570632 Review.
Is diabetic nephropathy reversible?
Fioretto P, Barzon I, Mauer M. Fioretto P, et al. Diabetes Res Clin Pract. 2014 Jun;104(3):323-8. doi: 10.1016/j.diabres.2014.01.017. Epub 2014 Jan 20. Diabetes Res Clin Pract. 2014. PMID: 24513120 Review.
205 results